Inês Martins, PhD, managing science editor —

Inês holds a PhD in biomedical sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied cell and molecular biology and worked as a research fellow at multiple institutes. In addition to several college awards, Inês won the Pfizer Basic Research Award in 2012 for a research paper. She also has a graduate degree in data science.

Articles by Inês Martins

Study: PRX-102 Is Safe, Slows Kidney Disease in Fabry Patients Previously Taking Replagal

One-year treatment with Protalix BioTherapeutics‘ investigational enzyme replacement therapy PRX-102 (pegunigalsidase alfa) is safe, well-tolerated and appears to more effectively slow kidney disease progression in Fabry disease patients previously treated with Replagal (agalsidase alpha), results from a Phase 3 clinical trial suggest. Patients also experienced…